keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer cytoreduction

keyword
https://www.readbyqxmd.com/read/28906381/comparison-of-secondary-cytoreductive-surgery-plus-chemotherapy-with-chemotherapy-alone-for-recurrent-epithelial-ovarian-tubal-or-peritoneal-carcinoma-a-propensity-score-matched-analysis-of-112-consecutive-patients
#1
Akimasa Takahashi, Kazuyoshi Kato, Motoki Matsuura, Takahiro Katsuda, Maki Matoda, Hidetaka Nomura, Sanshiro Okamoto, Hiroyuki Kanao, Eiji Kondo, Kohei Omatsu, Kuniko Utsugi, Nobuhiro Takeshima
To compare secondary cytoreductive surgery (SCS) plus chemotherapy with chemotherapy alone in Japanese patients with recurrent epithelial ovarian, tubal, or peritoneal cancer (ROC).From our institutional database, we identified 112 patients who underwent therapy for ROC between 2005 and 2013. Of the 112 patients, 77 received salvage chemotherapy alone (CT group) and 35 received SCS plus chemotherapy (SCS group). To reduce the impact of treatment selection bias on treatment outcomes, propensity score-matching analysis was used...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28888540/feasibility-safety-and-clinical-outcomes-of-cardiophrenic-lymph-node-resection-in-advanced-ovarian-cancer
#2
Renee A Cowan, Jill Tseng, Vijayashree Murthy, Radhika Srivastava, Kara C Long Roche, Oliver Zivanovic, Ginger J Gardner, Dennis S Chi, Bernard J Park, Yukio Sonoda
OBJECTIVES: Surgical resection of enlarged cardiophrenic lymph nodes (CPLNs) in primary treatment of advanced ovarian cancer has not been widely studied. We report on a cohort of patients undergoing CPLN resection during primary cytoreductive surgery (CRS), examining its feasibility, safety, and potential impact on clinical outcomes. METHODS: We identified all patients undergoing primary CRS/CPLN resection for Stages IIIB-IV high-grade epithelial ovarian cancer at our institution from 1/2001-12/2013...
September 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28885412/outcomes-associated-with-a-five-point-surgical-site-infection-prevention-bundle-in-women-undergoing-surgery-for-ovarian-cancer
#3
Melissa H Lippitt, Melissa Gerardi Fairbairn, Rayna Matsuno, Rebecca L Stone, Edward J Tanner, Elizabeth C Wick, Ana C Angarita, Kara Long Roche, Kimberly L Levinson, Jennifer E Bergstrom, Abdulrahman K Sinno, Melanie S Curless, Stephanie Wethington, Sarah M Temkin, Jonathan Efron, Deborah Hobson, Amanda N Fader
OBJECTIVE: To identify risk factors for surgical site infection and to define rates associated with cytoreductive surgery before and after implementation of an infection prevention bundle. METHODS: We conducted a prospective quality improvement study. Patients who underwent ovarian, fallopian tube, or peritoneal cancer cytoreductive surgery at an academic tertiary care center from April 2014 to April 2016 were prospectively enrolled. Patient demographics, surgical variables, and surgical site infection rates were compared with a historical cohort after introduction of a 5-point infection prevention bundle, including: 1) preoperative and intraoperative skin preparation with 4% chlorhexidine and intraoperative vaginal preparation with 4% chlorhexidine; 2) preoperative use of oral antibiotics and mechanical bowel preparation; 3) appropriate timing of intraoperative antibiotics; 4) adoption of enhanced sterile surgical techniques for colon procedures and incisional closure; and 5) perioperative incision management...
September 5, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28877609/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-the-treatment-of-advanced-epithelial-and-recurrent-ovarian-carcinoma-a-single-center-experience
#4
Maja J Pavlov, Miljan S Ceranic, Stojan M Latincic, Predrag V Sabljak, Dragutin M Kecmanovic, Paul H Sugarbaker
BACKGROUND: With standard treatment of epithelial ovarian cancer (EOC), prognosis is very poor. The aim of this study is to show early and late results in patients who underwent cytoreductive surgery and intraperitoneal chemotherapy. PATIENTS AND METHODS: This was a retrospective single centre study. All patients with advanced and recurrent ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) or modified early postoperative intraperitoneal chemotherapy (EPIC) were included in the study...
September 7, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28875365/the-preoperative-albumin-level-is-an-independent-prognostic-factor-for-optimally-debulked-epithelial-ovarian-cancer
#5
Ali Ayhan, Emre Günakan, İrem Alyazıcı, Nihan Haberal, Özden Altundağ, Polat Dursun
PURPOSE: A low albumin level has been reported to be a prognostic factor for various cancers. The aim of this study was to determine the association between preoperative serum albumin level and survival in patients with epithelial ovarian cancer (EOC). METHODS: Records of 337 patients with EOC that underwent optimal cytoreductive surgery were retrospectively reviewed. Threshold albumin level was planned as 32.5 g L(-1) due to the statistical analyses. RESULTS: Mean overall survival was 51...
September 5, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28871563/prognostic-value-of-the-age-adjusted-charlson-comorbidity-index-acci-on-short-and-long-term-outcome-in-patients-with-advanced-primary-epithelial-ovarian-cancer
#6
Annett Kahl, Andreas du Bois, Philipp Harter, Sonia Prader, Stephanie Schneider, Florian Heitz, Alexander Traut, Pier Francesco Alesina, Beate Meier, Martin Walz, Annettte Brueckner, Harald-Thomas Groeben, Violeta Brunkhorst, Sebastian Heikaus, Beyhan Ataseven
BACKGROUND: We evaluated the prognostic impact of the age-adjusted Charlson Comorbidity Index (ACCI) on both postoperative morbidity and overall survival (OS) in patients with advanced epithelial ovarian cancer (EOC) treated at a tertiary gynecologic cancer center. PATIENTS AND METHODS: Exploratory analysis of our prospectively documented tumor registry was performed. Data of all consecutive patients with stage IIIB-IV ovarian cancer who underwent primary cytoreductive surgery (PDS) from January 2000 to June 2016 were analyzed...
September 5, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28870790/adjuvant-intensity-modulated-whole-abdominal-radiation-therapy-for-high-risk-patients-with-ovarian-cancer-international-federation-of-gynecology-and-obstetrics-stage-iii-first-results-of-a-prospective-phase-2-study
#7
Nathalie Arians, Meinhard Kieser, Laura Benner, Nathalie Rochet, Sonja Katayama, Florian Sterzing, Klaus Herfarth, Kai Schubert, Lars Schröder, Christina Leitzen, Andreas Schneeweiss, Christof Sohn, Jürgen Debus, Katja Lindel
PURPOSE: To assess treatment tolerance and toxicity rates of consolidative whole-abdominal radiation therapy (WART) following cytoreductive surgery and carboplatin/paclitaxel chemotherapy in high-risk patients with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III) using intensity modulated radiation therapy. METHODS AND MATERIALS: The OVAR-IMRT-02 study is a multicenter, single-arm, phase 2 trial. Twenty patients with optimally debulked ovarian cancer (International Federation of Gynecology and Obstetrics stage III) with complete remission after chemotherapy were treated with intensity modulated WART as a consolidation therapy...
July 4, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28861808/a-review-of-thoracic-and-mediastinal-cytoreductive-techniques-in-advanced-ovarian-cancer-extending-the-boundaries
#8
REVIEW
Sara Nasser, Mara Kyrgiou, Jonathan Krell, Dimitrios Haidopoulos, Robert Bristow, Christina Fotopoulou
The aim of this study was to review the surgical and clinical outcomes of intrathoracic and mediastinal surgical cytoreduction in stage IV epithelial ovarian cancer (EOC). Relevant articles were identified from MEDLINE and EMBASE. Only analyses or reports that described actual intrathoracic cytoreduction via pleurectomy and/or resection of cardiophrenic/mediastinal lymph nodes were included. Imaging articles that merely described thoracic tumor patterns were excluded. A total of nine studies were identified, the oldest originating in 2007...
August 31, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28857784/barriers-to-primary-debulking-surgery-for-advanced-ovarian-cancer-in-latin-america
#9
Eduardo Paulino, Angelica Nogueira Rodrigues, Kathrin Strasser-Weippl, Jessica St Louis, Alexandra Bukowski, Paul E Goss
Ovarian cancer is gynecologic tumor with particularly high mortality because it is usually diagnosed in advanced stages. In Latin America and the Caribbean, it is the eighth most common malignancy in women, with an estimated 18,000 new cases and 11,500 deaths annually. Standard of care for women diagnosed with advanced ovarian cancer (AOC) is primary cytoreductive surgery followed by systemic chemotherapy using a combination of paclitaxel plus carboplatin. To pursue upfront surgery, highly specialized and well-trained gynecologic oncologists are required, in addition with well-equipped hospitals...
August 26, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28855982/peritoneal-metastases-of-rare-carcinomas-treated-with-cytoreductive-surgery-and-hipec-a-single-center-case-series
#10
Andreas Brandl, Christina Barbara Zielinski, Wieland Raue, Johann Pratschke, Beate Rau
INTRODUCTION: In selected cases, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for patients suffering from peritoneal metastases from colorectal, ovarian, gastric or appendiceal origin. The effectiveness of this extensive has not been elucidated within other rare diseases by now. METHODS: We conducted a retrospective analysis of patients treated with CRS for peritoneal carcinomatosis during the period between July 2010 and September 2015...
October 2017: Annals of Medicine and Surgery
https://www.readbyqxmd.com/read/28845013/-progress-in-preoperative-evaluation-methods-regarding-cytoreduction-in-patients-with-advanced-ovarian-cancer
#11
Jinyang Liu, Keqiang Zhang
Primary cytoreductive surgery followed by platinum-based chemotherapy represents the standard treatment for patients with advanced ovarian cancer. But some patients with advanced ovarian cancer still have suboptimal residual disease after the primary debulking surgery. Neoadjuvant chemotherapy has been suggested as an alternative strategy to achieve no residual disease. It is important to find methods to estimate the likelihood that cytoreductive surgery will leave no residual disease. A number of studies have evaluated the use of serologic markers (such as CA-125), imaging modalities (such as CT, PETCT, MRI), and laparoscopic surgery to determine which patients are ideal predictors for neoadjuvant chemotherapy...
July 28, 2017: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/28836469/improved-killing-of-ovarian-cancer-stem-cells-by-combining-a-novel-chimeric-antigen-receptor-based-immunotherapy-and-chemotherapy
#12
Rüdiger Klapdor, Shuo Wang, Ulrich Hacker, Hildegard Büning, Michael Morgan, Thilo Dörk, Peter Hillemanns, Axel Schambach
Ovarian cancer represents the most lethal gynecological cancer. Although cytoreductive chemotherapy and surgery lead to complete macroscopic tumor removal, most of the patients in advanced stages suffer from recurrent disease and subsequently die. This may be explained by the activity of cancer stem cells (CSC), which are a subpopulation of cells with an elevated chemoresistance and an increased capacity for self-renewal and metastatic spread. Specifically targeting these cells by adoptive immunotherapy represents a promising strategy to reduce the risk for recurrent disease...
August 24, 2017: Human Gene Therapy
https://www.readbyqxmd.com/read/28823141/targeted-therapy-of-ovarian-cancer-including-immune-check-point-inhibitor
#13
REVIEW
Jin Young Kim, Chi Heum Cho, Hong Suk Song
Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate of ovarian cancer remains high. Attempts to improve this standard two-drug chemotherapy by adding a third cytotoxic drug have failed to affect either progression-free survival or overall survival and have resulted in an increase in toxic side effects...
September 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28822556/associations-between-residual-disease-and-survival-in-epithelial-ovarian-cancer-by-histologic-type
#14
Alexander Melamed, Beryl Manning-Geist, Amy J Bregar, Elisabeth J Diver, Annekathryn Goodman, Marcela G Del Carmen, John O Schorge, J Alejandro Rauh-Hain
OBJECTIVE: Surgical cytoreduction has been postulated to affect survival by increasing the efficacy of chemotherapy in ovarian cancer. We hypothesized that women with high-grade serous ovarian cancer, which usually responds to chemotherapy, would derive greater benefit from complete cytoreduction than those with histologic subtypes that are less responsive to chemotherapy, such as mucinous and clear cell carcinoma. METHODS: We conducted a retrospective cohort study of patients who underwent primary cytoreductive surgery and adjuvant chemotherapy for stage IIIC or IV epithelial ovarian cancer from 2011 to 2013 using data from the National Cancer Database...
August 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800940/neoadjuvant-chemotherapy-and-chemotherapy-cycle-number-a-national-multicentre-study
#15
Alon D Altman, Jacob McGee, Taymaa May, Kelly Lane, Lin Lu, Wei Xu, Prafull Ghatage, Barry Rosen
OBJECTIVES: Six cycles of consolidation chemotherapy have become the standard for ovarian cancer treatment regimen following primary cytoreduction, yet with neoadjuvant chemotherapy (NAC), only 3 consolidation cycles are used. This study examines the effects of number of chemotherapy cycles in women with ovarian cancer that are being treated with neoadjuvant chemotherapy. In addition, we examined the effect of number of cycles on survival on consolidation and total chemotherapy. METHODS: All patients with stage IIIC and IV high grade serous carcinoma (HGSC) were identified at 4 major Canadian cancer centers treated with NAC...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28795373/implementation-of-extensive-cytoreduction-resulted-in-improved-survival-outcomes-for-patients-with-newly-diagnosed-advanced-stage-ovarian-tubal-and-peritoneal-cancers
#16
Francesco Raspagliesi, Giorgio Bogani, Antonino Ditto, Fabio Martinelli, Valentina Chiappa, Chiara Borghi, Cono Scaffa, Federica Morano, Giuseppa Maltese, Domenica Lorusso
BACKGROUND: Residual disease (RD) after primary debulking surgery (PDS) is one of the main factors driving ovarian cancer prognosis. The primary end point of this study was assessment of the impact that surgery had on survival outcomes for patients with advanced ovarian cancer. METHODS: Data on the effect of newly diagnosed advanced-stage ovarian, tubal, and peritoneal cancers were analyzed during two study periods (T1: 2001-2006 and T2: 2007-2012), in which the concepts of optimal and complete cytoreduction were introduced and implemented...
August 9, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28791266/prognostic-assessment-of-sarcomatous-histologic-subtypes-of-ovarian-carcinosarcoma
#17
Hyun Jin Kim, Hyun-Mi Lee, Mi Kyung Kim, Yoo-Kyung Lee, In-Ho Lee, Ki-Heon Lee, Hyesun Kim
OBJECTIVE: Ovarian carcinosarcoma is a rare subtype of this disease that has not been thoroughly investigated. The aim of this study was to evaluate the prognostic factors and out comes in patients with ovarian carcinosarcoma. METHODS: All patients with histologically confirmed ovarian carcinosarcoma who were treated at Cheil General Hospital and Women's Healthcare Center between January 2000 and December 2015 were identified and analyzed. Data were extracted from medical records, and statistical analyses were performed to determine correlations between clinicopathological parameters and survival outcomes...
July 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28774462/cytoreduction-of-bulky-para-aortic-lymphadenopathy-from-metastatic-ovarian-cancer
#18
Chahien Choi, Woo Young Kim, Dong Hee Lee, Sam Sae Oh
No abstract text is available yet for this article.
July 31, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28774461/phase-ii-trial-of-bevacizumab-with-dose-dense-paclitaxel-as-first-line-treatment-in-patients-with-advanced-ovarian-cancer
#19
Nicole D Fleming, Robert L Coleman, Celestine Tung, Shannon N Westin, Wei Hu, Yunjie Sun, Priya Bhosale, Mark F Munsell, Anil K Sood
OBJECTIVES: To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer. METHODS: After IRB approval, this single-institution, phase II study enrolled patients with stage III or IV epithelial ovarian cancer after primary cytoreductive surgery to treatment with carboplatin (AUC 5), weekly paclitaxel (80mg/m2), and bevacizumab (15mg/kg) every 3weeks for at least 6cycles...
October 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28772202/the-role-of-surgical-excision-for-the-krukenberg-tumour-a-case-report
#20
David Lam, Eugene Ong
INTRODUCTION: Krukenberg tumour (KT), which represents carcinoma in the ovary, is an uncommon manifestation of metastatic colorectal cancer. It is associated with poor prognosis and a high incidence of peritoneal metastatic disease. PRESENTATION OF CASE: The authors present a case of a 51-year-old female who had a symptomatic, metachronous right ovarian KT diagnosed 12 months after her initial resection. Surgery was performed to excise the 23cm tumour as well as the contralateral ovary and isolated peritoneal disease, with an R0 resection achieved...
2017: International Journal of Surgery Case Reports
keyword
keyword
111476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"